Cytodyn Inc (CYDY)

[tonysd57]

Or we all could have bought Tobira Theraputics last July went it tanked to $4.00 after it's lead NASH drug therapy "cenicrivoric" failed to meet trial primary endpoints, which naturally led to Allergen buying them for almost $30.00 per share a few months later in September. Allergen's explanation to shareholders was
"we saw enough promise in the failed trials" to warrant the outlay-

Point being, CYDY is going to be bought. The labeling isn't going to be our problem, nor will listening to the endless whining regarding short term financing and dilution. The technology is best in class and has a myriad of potential applications-

I recall an interesting article in The Economist from 2015 regarding the predictions of Gileads demise by 2020 due to it's heavy reliance on HIV product income and how new/novel therapies would steal 85-90% of their customers. Within the publication was a list of approximately 20 companies ( PRO-140 among them) that had a variety of Ph 1/11 studies underway -

The authors believed it would be the gene editing / entry inhibitors in trials at Sangamo BioSciences that would win the race. They're still treading water in Phase II and turned attention to hemophilia I believe- if the combo trial results mimic past results, I can't see us owning this stock by end of year-